Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
Status:
Active, not recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Phase II study with a two-stage design to evaluate efficacy and safety of ibrutinib in
combination with rituximab (I+R) in untreated patients with indolent clinical forms of MCL.
An extensive biological study will be conducted in order to further characterize this
population of MCL patients and evaluate the response obtained with the mutational profile of
the tumor.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea